Skip to main content

Meisner Lara's Form 4 filing

Viridian Therapeutics, Inc. (VRDN) · filed Jan 25, 2023

Accession no.
0000899243-23-002674
Filed
Jan 25, 2023
Trade date
Jan 23, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $244.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Meisner LaraCIK 0001883986Officer (General Counsel and Secretary)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 23, 2023Common StockMOption exerciseAcquired+4,971$23.03+$114,482.134,971Direct
Jan 23, 2023Common StockMOption exerciseAcquired+1,872$14.00+$26,2086,843Direct
Jan 23, 2023Common StockSSaleDisposed−6,843$35.66−$244,021.380Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 23, 2023Common StockMOption exerciseDisposed−4,971$0.00$039,750Direct
Jan 23, 2023Common StockMOption exerciseDisposed−1,872$0.00$020,003Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)